How does Totally plc's go-to-market design target NHS and HSE buyers to close capacity gaps?
Totally plc's sales motion focuses on procurement-led deals with NHS and HSE buyers, selling insourcing and urgent-care capacity during waiting-list surges. In 2025 it won multiple short-term contracts after increased elective backlog funding, showing buyer urgency and revenue spikes.
Prioritise procurement teams and clinical commissioners; tender speed wins conversion. See service risks and policy context in Totally PESTLE Analysis.
Which Buyers Has Totally Chosen to Target?
Totally Company targets public-sector commissioners as its primary buyers, focusing on NHS England Integrated Care Boards, NHS Foundation Trusts, and Ireland's HSE, while corporate occupational-health purchasers serve as secondary commercial targets.
Main economic buyer: Public-sector commissioners
NHS England Integrated Care Boards (ICBs) and NHS Foundation Trusts are the core decision-makers for contracts tied to Referral to Treatment (RTT) backlog reduction; Ireland's HSE is the primary buyer in the Republic. These institutions control capital and operational budgets aligned to waiting-list targets and population health metrics.
Secondary buyers: Corporate occupational-health clients
Large employers and occupational-health providers buy elective and wellbeing services to reduce staff absenteeism and improve productivity. This B2B channel diversifies revenue away from sole reliance on public-sector procurement cycles.
Chosen commercial segment: Population health & waiting-list management
The commercial model is built to win contracts focused on reducing RTT backlogs-about 7.6-7.8 million open pathways in 2024-and managing elective-care pathways at scale for defined populations. Contracts emphasize measurable KPIs: wait-time reduction, throughput, and outcomes.
Why this buyer choice matters to Totally's GTM
Targeting commissioners aligns pricing and product positioning with budget holders who can commit multi-year contracts and scale deployments across systems. Focusing on ICBs/Trusts/HSE accelerates revenue predictability and ties Totally Company go-to-market strategy directly to national waiting-list policy levers.
Patients (adults 35-75 for elective care; families and elderly for urgent care) are end-users, not payers; commercial efforts prioritize institutional procurement, contract structuring, and ROI metrics tied to population health targets. See Market Segmentation of Totally Company for deeper segmentation context: Market Segmentation of Totally Company
Totally SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
How Does Totally's Go-to-Market System Reach Them?
Totally Company's go-to-market system reaches buyers through national and regional NHS procurement frameworks, trust-level tenders, and direct institutional bidding led by a professional bid team targeting Medical Directors, procurement leads, and ICB commissioners.
Procurement frameworks and trust tenders
The primary acquisition route is national and regional NHS frameworks plus trust-level tenders, which standardize access to large outsourcing contracts across the UK health system.
Direct institutional engagement
A professional bid team conducts offline outreach to Medical Directors, procurement leads, and ICB commissioners to influence specifications and submit compliant bids.
Sales channels and contract structure
Sales focus is on multi-year, turnkey capacity contracts valued typically between 3,000,000 and 25,000,000 GBP per annum, delivered via framework call-offs or direct trust awards.
Demand-generation and credibility tactics
Totally uses clinical evidence, performance metrics (2-hour/4-hour urgent care targets), and consistent Good CQC ratings as demand levers in bid narratives and commissioner briefings.
Acquisition efficiency and bid success
Centralized bid operations, template-led submissions, and measurable clinical KPIs compress sales cycles and raise hit rates for large-scale NHS tenders.
Strongest reach advantage
The combination of framework access plus verifiable operational performance (CQC Good, urgent care targets) creates a defensible, scalable route to enterprise NHS buyers.
The GTM system wins institutional buyers by aligning procurement compliance with clinical outcomes and presenting turnkey capacity at scale.
How the Go-to-Market System Reaches Buyers
Totally Company reaches NHS buyers through framework call-offs and trust tenders, supported by a specialist bid team that foregrounds clinical evidence and performance metrics to secure multi-million pound contracts.
- Primary route-to-market: national and regional NHS frameworks plus trust-level tenders
- Most important digital or sales channel: direct institutional bidding and targeted commissioner engagement
- Key demand-generation tactic: use of CQC ratings and urgent care KPI evidence in bids and briefings
- Strongest reach advantage: turnkey, large-scale capacity offers worth 3,000,000-25,000,000 GBP per year anchored to demonstrable clinical performance
See the Operating Model of Totally Company for additional context: Operating Model of Totally Company
Totally PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
How Does Totally Convert Interest into Economic Value?
Totally Company converts institutional interest into revenue via multi-year service contracts tied to throughput and performance KPIs, monetizing hospital trust capacity through an insourcing model that deploys clinical teams to run theatres on weekends and evenings.
Direct enterprise contracts as the core sales model
Totally plc sells primarily through direct enterprise contracts with NHS trusts and healthcare providers, using sales teams and senior clinical leads to secure 2-5 year agreements based on guaranteed throughput and service-level KPIs.
Throughput-and-performance pricing and monetization
Pricing ties fees to procedure throughput and outcomes: fixed minimum payments plus per-case or per-session fees; the insourcing model converts idle operating theatres into billable sessions, creating incremental revenue from existing trust assets.
Operational performance and KPI delivery drive conversion
Conversion hinges on demonstrable backlog reduction and clinical throughput; evidence such as reducing gynecology waits from 90 weeks to 9 weeks in 2024 is used in procurement pitches to convert interest into signed contracts.
Retention, renewals, and anchor-contract dependence
Revenue repeatability depends on contract renewals and anchor deals; gross margin compressed to 16.6 percent by March 2024, and the loss of the £13 million NHS 111 national resilience support contract in February 2025 created an immediate revenue shortfall, showing high dependency on key agreements.
Key economic levers: optimize theatre utilization to raise per-session yield, protect anchor contracts to avoid sudden revenue holes, and improve gross margin above 16.6 percent by shifting mix toward higher-margin elective work; see Governance Structure of Totally Company for governance context.
Totally Marketing Mix
- Complete Marketing Mix Analysis
- Effortlessly Communicate Your Business Strategy
- Investor-Ready Format
- 100% Editable and Customizable
- Clear and Structured Layout
What Does Totally's Commercial Model Suggest About Strategic Effectiveness?
The Totally Company commercial model shows strong focus and scale but weak resilience: it efficiently captured outsourced urgent care but concentrated revenue and thin margins made the GTM fragile and high-risk.
Public healthcare contracting as dominant channel
Focusing on large NHS and integrated care board (ICB) contracts delivered rapid scale and market share in urgent care and insourcing.
High-ticket contract conversion
Winning multi-million-pound public contracts boosted revenue per deal and raised utilization of clinical rosters, improving apparent sales efficiency.
Revenue concentration and contract termination risk
Dependence on a small number of large NHS contracts created single-point failures; non-renewals or performance terminations rapidly eroded cash flow.
Effective for growth, poor for resilience
The GTM was highly effective at scaling but lacked diversification and margin cushion, contributing to administration in June 2025 despite high asset value.
Financials and outcomes frame the strategic judgment: revenue fell 21 percent to 106.7 million GBP for year ending 31 March 2024, with a loss before tax of 3.9 million GBP, and administration in June 2025.
What the Commercial Model Suggests About Strategic Effectiveness
The commercial model shows a clear trade-off: a GTM tailored to win large public-sector contracts delivered rapid scale but created acute exposure to contract volatility and government funding cycles.
- Dominant buyer/channel: large NHS and ICB contracts drove most revenue
- Conversion strength: ability to close high-value, multi-year public contracts
- Main weakness: extreme revenue concentration and low margin buffer versus contract risk
- Overall judgment: strategically effective for market capture but operationally misaligned with B2G revenue risk, leading to insolvency in 2025
See further analysis in Strategic Position of Totally Company
Totally Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
Related Blogs
- What Can Totally Company's History Teach as a Business Case?
- How Does the Governance Structure of Totally Company Shape Strategy?
- How Does Totally Company Segment and Target Its Market?
- How Does Totally Company's Operating Model Create Value?
- What Does Totally Company's Strategic Growth Path Look Like?
- What Is Totally Company's Strategic Position in Its Market?
- What Do the Strategic Principles of Totally Company Reveal?
Frequently Asked Questions
Totally targets public-sector commissioners as its primary buyers, focusing on NHS England Integrated Care Boards, NHS Foundation Trusts, and Ireland's HSE. Corporate occupational-health purchasers serve as secondary targets. The commercial segment centers on population health and waiting-list management to reduce RTT backlogs of 7.6-7.8 million open pathways in 2024.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.